Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03066739 · ClinicalTrials.gov registry record · Phase 2
Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia
A Phase 2 study, sponsored by University of California, Irvine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT03066739 is a Phase 2 study that was terminated before completion, run by University of California, Irvine. The registered enrollment target is 8 participants.
The verdict
NCT03066739, a Phase 2 study, was terminated before completion, sponsored by University of California, Irvine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether using ultra-low dose naloxone, an opioid antagonist, has the potential to block remifentanil-induced hyperalgesia and tolerance following surgery. There are 3 study groups: (1) low dose remifentanil (LO, 0.1 micrograms/kg/mL), (2) high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL), or (3) high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone). The hypothesis of the study is that occurrence of remifentanil-induced hyperalgesia (low score in mechanical pain threshold) in the HN group will be lower than in the HI group.
Interventions
- DRUG Remifentanil
- DRUG Remifentanil+ Placebo
- DRUG Remifentanil +ultra-low dose naloxone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-02-25 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03066739
The ClinicalTrials.gov registry entry for NCT03066739 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Remifentanil is the first listed.
NCT03066739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03066739 about?
NCT03066739 is a clinical study titled "Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia". The purpose of this study is to evaluate whether using ultra-low dose naloxone, an opioid antagonist, has the potential to block remifentanil-induced hyperalgesia and tolerance following surgery. There are 3 study groups: (1) low dose remifentanil (LO, 0.1 micrograms/kg/mL), (2) high dose remifenta...
What is the current status of trial NCT03066739?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2023-02-25. Estimated completion is 2025-12-01.
What interventions are being tested in trial NCT03066739?
The interventions under investigation include: Remifentanil (DRUG), Remifentanil+ Placebo (DRUG), Remifentanil +ultra-low dose naloxone (DRUG).
Who is sponsoring clinical trial NCT03066739?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.